The burden of COPD in Italy: results from the Confronting COPD survey
The burden of COPD in Italy: results from the Confronting COPD survey
复制标题
DOI：
10.1016/s0954-6111(03)80024-0
复制
发表时间：
2003-03-01
影响因子：
4.3
通讯作者：
Cerveri, I
中科院分区：
文献类型：
--
作者：
Dal Negro, R;Rossi, A;Cerveri, I
慢性阻塞性肺疾病（COPD）是一种以不完全可逆的气流受限和进行性肺功能下降为特征的疾病状态。在意大利，估计有2-6百万男性和女性患有COPD，并且该疾病每年导致约18000人死亡。除了死亡率之外，COPD的发病率导致大量使用二级医疗保健资源。意大利的COPD负担可能是由于医疗保健专业人员对疾病诊断不足，特别是在疾病的早期阶段，以及医生对推荐的治疗实践缺乏认识。为了解决COPD负担信息的需求，一项名为“在北美和欧洲面对COPD”的大规模国际调查评估了临床结局、医疗保健资源的使用和工作场所生产力的损失，以及意大利和其他六个国家这种疾病的经济成本。在意大利，调查数据的经济分析显示，COPD给医疗保健系统带来的平均年成本为每位患者1261.25欧元。间接成本估计为每位患者47.29欧元，使该疾病的社会成本达到每位患者1308.54欧元。意大利COPD患者人均直接费用的四分之三来自住院治疗（963.10欧元），这表明旨在预防加重的干预措施可以减轻意大利COPD的负担。COPD对意大利医疗保健系统的高度影响也可能是疾病诊断不足和治疗不足的结果，这表明可以通过增加使用肺量测定作为诊断工具来降低成本，并提高医生对治疗指南的依从性。患有重度COPD和其他合并症的患者的费用（分别为6366欧元和1861欧元）高于轻度疾病（441欧元）或无合并症（1021欧元）的患者，这表明戒烟干预对预防疾病进展的重要性。
Chronic obstructive pulmonary disease (COPD) is a disease state characterized by airflow limitation that is not fully reversible, and progressive lung function decline. In Italy, an estimated 2-6 million men and women have COPD, and the disease causes, around 18000 deaths each year In addition to mortality, morbidity from COPD results in substantial use of secondary healthcare resources. The burden of COPD in Italy may be due to the underdiagnosis of the disease by healthcare professionals, particularly in the early stages of the disease, and a lack of awareness among physicians of recommended treatment practices. In an attempt to address the need for information on the burden of COPD, a largescale international survey, Confronting COPD in North America and Europe, assessed clinical outcomes, use of healthcare resources and loss of productivity in the workplace, and the economic cost of this disease in Italy and six other countries. In Italy, the economic analysis of the survey data showed that the mean annual cost of COPD to the healthcare system was 1261.25 euro per patient. Indirect costs were estimated at 47.29 euro per patient, bringing the societal cost of the disease to 1308.54 euro per patient. Three-quarters of the direct per patient cost of COPD in Italy were accounted for by inpatient hospitalizations (963.10 euro), suggesting that interventions aimed at preventing exacerbations could alleviate the burden of COPD in Italy. The high impact of COPD on the Italian healthcare system is also likely to be a consequence of the underdiagnosis and undertreatment of the disease, suggesting that costs may be reduced by increasing the utilization of spirometry as a diagnostic tool, and improving physician adherence to treatment guidelines. Patients with severe COPD and other comorbidities showed higher costs (6366 Euro and 1861 Euro, respectively) than patients with mild disease (441 Euro) or no comorbidities ( 1021 Euro), underlying the importance of smoking cessation interventions to prevent disease progression.